India’s Symbiotec Pharmalab Target Of 25% Acquisition By U.K. Fund Actis
This article was originally published in PharmAsia News
Executive Summary
Symbiotec Pharmalab is the target of an attempt by U.K. investor Actis to buy a 25% stake for $50 million, according to sources.